NuCana PLC
NASDAQ:NCNA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.86
256
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Relative Value
There is not enough data to reliably calculate the relative value of NCNA.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
NCNA Competitors Multiples
NuCana PLC Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
|
NuCana PLC
NASDAQ:NCNA
|
16.5m USD | 0 | -0.4 | 0.7 | 0.7 | |
| IL |
C
|
Can Fite Biopharma Ltd
TASE:CANF
|
707T ILS | 255 921 586.5 | -17 575 047.8 | -17 246 503.8 | -17 208 113.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 865 457.5 | -160 957.5 | -195 453.7 | -193 223.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
391.9B USD | 6.6 | 166.9 | 16.2 | 23 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
173.8B USD | 4.8 | 24.8 | 18 | 18 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
149.7B USD | 5.1 | 18.5 | 12.4 | 12.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.8B USD | 10.1 | 32.1 | 23.5 | 24.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 080.3 | -530.8 | -578 | -562.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD | 5.7 | 17.9 | 17.1 | 19.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
81.5B AUD | 3.5 | 18.2 | 12.4 | 15.4 | |
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
51.2B USD | 15.9 | 1 175.1 | 158.4 | 192.1 |
